EW Filing
4Filing Date: May 22, 2026
Edwards Lifesciences Corp (EW) · Insider Trading (Form 4) SEC Filing
Statement of Changes in Beneficial Ownership
descriptionView SEC Filing
ACC: 0001225208-26-005576open_in_new
Total Value$126.9K
Trades1
Insiders1
Transaction Details
Chopra Daveen
CVP, TMTT & Surgical·Direct
Sell · Dispose
Common Stock
Shares-1.50K
Price$84.60
Total Value$126.9K
Shares Owned After44.32K
Transaction DateMay 22, 2026
Footnotes ▸
This transaction was executed in multiple trades at prices ranging from $84.6002 to $84.6050. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Post-Transaction Holdings
Chopra Daveen
| Security | Shares | Change |
|---|---|---|
| Common Stock | 44.32K | -1.50K (-3.27%) |
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership ===
Document Type: 4
Period of Report: 2026-05-22
10b5-1 Pre-arranged Plan: No
--- Issuer ---
Name: Edwards Lifesciences Corp (EW)
CIK: 0001099800
--- Reporting Owner ---
Name: Chopra Daveen
CIK: 0001740963
Role: Officer (CVP, TMTT & Surgical)
--- Non-Derivative Transactions ---
[Transaction #1]
Security: Common Stock
Date: 2026-05-22 | Code: S (Open market sale)
Shares: -1,500 | Price: $84.60
Total Value: $126,905.25
Shares Owned After: 44,324 | Ownership: D (Direct)
Footnotes:
[F1] This transaction was executed in multiple trades at prices ranging from $84.6002 to $84.6050. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
--- Footnotes (Complete Index) ---
F1: This transaction was executed in multiple trades at prices ranging from $84.6002 to $84.6050. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
--- Signature ---
/s/ Linda J. Park, Attorney-in-Fact (2026-05-22)